華檢醫療(01931.HK)與仁和藥業全資附屬仁和國際達成重大戰略合作 共同於美國籌建全球首個專注於OTC領域的垂直RWA交易所
格隆匯9月16日丨華檢醫療(01931.HK)宣佈，集團與仁和藥業(000650.SZ)間接全資附屬公司仁和國際達成戰略合作，雙方將共同創立全球範圍內首個專注於非處方藥(OTC)細分領域的現實世界資產(RWA)專業化交易平臺。該平臺將嚴格遵循證券級標準進行設計與運營，致力於爲OTC行業的知識產權、未來收益權、品牌價值等無形資產以及實體產品權益，提供一個高效、透明、且合規的數字化交易與價值發現場所，填補全球市場的關鍵空白。
據悉，仁和藥業作爲中國非處方藥物(OTC)協會會長單位，不僅深度參與行業政策研討與標準制定，更憑藉其在中國OTC市場極具競爭力的穩固份額，持續引領產業發展方向。公司在OTC領域具備廣泛的行業號召力與話語權，其戰略動向與業務創新已成爲觀測中國OTC市場發展趨勢的重要風向標。
此次與仁和藥業的戰略合作，標誌着集團「ETHK」鏈上金融生態戰略進入了規模化落地與價值實現的新階段，亦是其創新的「ETHK全球RWA交易•所中所」商業模式在全球舞臺的首次重磅亮相與實踐驗證。此舉深刻體現了集團在「聚焦核心戰略、實現規模化複製、構建差異化優勢」上的卓越規劃與執行能力，彰顯了集團致力於通過前沿創新技術與嚴謹的合規實踐，構建一個真正開放、賦能、共榮的數字金融新生態的決心。
華檢醫療堅信，金融科技的終極使命在於服務實體經濟，創造普惠價值。此次合作正是對這一信念的生動詮釋。集團旨在通過科技賦能，助力仁和藥業這樣的經典民族品牌完成數字化躍遷，並將其成功的生態模式推廣至各行各業，最終服務於國家產業升級與數字經濟發展的宏大敘事，踐行我們「利國利民利天下」的企業初心與終極願景。我們期待，這座全球首創的OTCRWA交易所不僅能成爲價值流通的平臺，更能成爲全球創新健康資源與龐大中國市場需求之間的超級連接器，爲提升人類健康福祉貢獻一份力量。
董事會深信，此次強強聯合將產生巨大的協同效應，不僅對雙方企業的戰略轉型與價值重估產生深遠且積極的推動，更將爲集團未來可持續的業務增長與財務表現注入強勁動力。集團將與仁和藥業緊密協作，匯聚雙方優勢資源，全力確保該全球首家OTCRWA交易所的高標準、高質量成功落地與穩健運營，攜手共創未來。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
